Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults

NCT05297578 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

207

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumococcal Vaccines

Interventions

BIOLOGICAL: 24-Valent Pneumococcal Conjugate Vaccine
BIOLOGICAL: Pneumococcal 20-valent Conjugate Vaccine

Sponsor

Vaxcyte, Inc.